Tamper-evident packaging requirements for over-the-counter human drug products--FDA. Final rule.
The Food and Drug Administration (FDA) is amending its regulations on tamper-resistant packaging to require that all over-the-counter (OTC) human drug products marketed in two-piece, hard gelatin capsules be sealed using a tamper-evident technology; to change the term "tamper-resistant" in the labeling of all OTC drug products to "tamper-evident;" and to specify that the required OTC drug product labeling statement must refer to all packaging features used to comply with the tamper-evident packaging requirements, including those on the secondary package, the immediate container or closure, and any capsule sealing technologies used. FDA is taking this action as a result of its continuing review of the potential public health threat posed by product tampering and to improve consumer protection by addressing specific vulnerabilities in the OTC drug market.
D003415:Crime / Q000517:prevention & control*; D004349:Drug Packaging / Q000331:legislation & jurisprudence*; D006801:Humans; D004366:Nonprescription Drugs / Q000592:standards*; D012637:Security Measures / Q000331:legislation & jurisprudence; D014481:United States; D014486:United States Food and Drug Administration
D004366:Nonprescription Drugs